DDInter986 DDInter1082
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Isoniazid {u} (Compound) binds {v} (Gene) CYP3A4
Isoniazid {u} (Compound) causes {v} (Side Effect) Pyridoxine deficiency
Isoniazid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Methylprednisolone
Isoniazid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludrocortisone
Isoniazid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pioglitazone
Isoniazid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Isoniazid {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Isoniazid (Compound) binds CYP3A4 (Gene)
Isoniazid (Compound) causes Pyridoxine deficiency (Side Effect)
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Isoniazid may lead to a major life threatening interaction when taken with Leflunomide